Distinct functions of retinoic acid receptor beta isoforms: implications for targeted therapy

Area of Science:

• Molecular Biology
• Pharmacology
• Genetics

Background:

• Vitamin A derivatives (retinoids) are crucial for tissue development and disease treatment.
• Retinoid actions are mediated by retinoic acid receptors (RARs) and retinoid X receptors (RXRs).
• RARbeta isoforms play distinct roles in mediating retinoid therapeutic effects, including cancer chemoprevention and dermatologic treatments.

Purpose of the Study:

• To review the structure and function of RARbeta isoforms.
• To discuss recent advancements in the epigenetic targeting of specific RARbeta isoforms.
• To highlight the importance of isoform-specific functions for optimizing retinoid-based therapies.

Main Methods:

• Literature review focusing on RARbeta isoform structure, function, and epigenetic targeting.
• Analysis of studies investigating isoform-specific gene induction patterns and biological consequences.
• Examination of research on combining retinoids with chromatin-modifying drugs.

Main Results:

• Five human RARbeta isoforms exist, with specific isoforms exhibiting distinct or opposing functions.
• Functional isoforms (RARbeta1', RARbeta2) activate unique gene sets, while dominant-negative isoforms (RARbeta4, RARbeta5) inhibit gene activation.
• RARbeta1's role as a potential oncogene in certain cancers is noted, and chromatin-modifying drugs can induce isoform-specific changes in the RARbeta gene.

Conclusions:

• Discerning the precise functions of individual RARbeta isoforms is critical for advancing retinoid therapy.
• Targeting specific RARbeta isoforms offers potential for more effective and personalized retinoid treatments.
• Combining retinoids with chromatin-modifying drugs presents a promising strategy for rational therapeutic approaches.